PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation
- 7 July 2009
- journal article
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 35 (2) , 213-217
Abstract
Background/Aims: Antiplatelet therapy with aspirin and clopidogrel is an important component of the management of acute coronary syndrome, but it also increases the risk of bleeding. There are no formal guidelines about the use of a proton pump inhibitor (PPI) for gastroprotection in patients on clopidogrel. This study assessed how many patients in the Royal Darwin Hospital (RDH) and the Royal Hobart Hospital (RHH) prescribed clopidogrel and at risk of bleeding were co‐prescribed PPIs. Methods: We conducted a retrospective cohort study using a pharmacy database to select all patients commenced on clopidogrel in a 1‐year period. We identified all patients newly prescribed clopidogrel and determined the proportion that had a risk factor for bleeding and also received a PPI. We also assessed the effect of the use of PPIs on the number of reported bleeds. Results: The final study cohort consisted of 385 patients who had been newly prescribed clopidogrel. Of all patients discharged on clopidogrel, 95·6% (368/385) had ≥1 risk factor for bleeding. One hundred and twenty‐eight of these patients [128/368, (34·8%)] were discharged on a PPI. Patients on dual antiplatelet therapy with an additional risk factor for bleeding and not discharged on a PPI were more likely to develop a major bleed than patients on dual antiplatelet therapy without a risk factor for bleeding not discharged on a PPI (11·1% vs. 1·8%; P < 0·01). Patients on dual antiplatelet therapy with an additional risk factor for bleeding not discharged on a PPI had a higher probability (borderline significance) of major bleeding, compared with patients on dual antiplatelet therapy with an additional risk factor for bleeding discharged on a PPI [PPI: 1/60, (1·7%) vs. no PPI: 6/54, (11·1%); P = 0·05]. Conclusions: Our results indicate that PPIs may only lower the probability of major bleeding in patients treated with dual antiplatelet therapy, who possess additional risk factor(s) for bleeding.Keywords
This publication has 14 references indexed in Scilit:
- Upper Gastrointestinal Bleeding in Patients with Aspirin and Clopidogrel Co-TherapyDigestion, 2008
- Upper Gastrointestinal Bleeding in Patients With Acute Coronary SyndromesJournal of Clinical Gastroenterology, 2008
- Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With AspirinJACC, 2008
- Evaluation of Proton Pump Inhibitor Use in Patients With Acute Coronary Syndromes Based on Risk Factors for Gastrointestinal BleedCritical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2007
- Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery?Interactive CardioVascular and Thoracic Surgery, 2007
- Predictors and outcomes associated with gastrointestinal bleeding in patients with acute coronary syndromesJournal of Thrombosis and Thrombolysis, 2006
- Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 2006
- Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: Where we are now?Platelets, 2006
- Upper gastrointestinal bleeding associated with antiplatelet drugsAlimentary Pharmacology & Therapeutics, 2005
- Comparative Safety and Tolerability of Clopidogrel and AspirinDrug Safety, 1999